MedTrace Logo

A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia

NCT03542851 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-04-29

No results posted yet for this study

Summary

This is a randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with Idiopathic Hypersomnia.

Conditions

  • Idiopathic Hypersomnia

Interventions

DRUG

Pentetrazol (PTZ)

BTD-001 is an oral capsule of PTZ.

DRUG

Placebo oral capsule

Placebo will be presented as oral capsule.

Sponsors & Collaborators

  • Balance Therapeutics

    lead INDUSTRY

Principal Investigators

  • Morgan Lam · Chief Operating Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-29
Primary Completion
2020-05-01
Completion
2020-05-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03542851 on ClinicalTrials.gov